免疫性血小板减少症在多发性原发肿瘤中的作用

Q4 Medicine
R. V. Vardanyan, S. G. Zakharov, T. A. Mitina, P. A. Zeynalova, Yu. Yu. Chuksina, A. V. Zakharova
{"title":"免疫性血小板减少症在多发性原发肿瘤中的作用","authors":"R. V. Vardanyan, S. G. Zakharov, T. A. Mitina, P. A. Zeynalova, Yu. Yu. Chuksina, A. V. Zakharova","doi":"10.17650/1818-8346-2023-18-3-44-49","DOIUrl":null,"url":null,"abstract":"Multiple primary malignant neoplasms (MPMNs) is a complex process in which the development of 2 or more neoplasms simultaneously or after a certain interval is observed. MPMNs develop independently from each other within one or more organs. Many etiopathogenetic factors can cause MPMNs. Numerous studies have been conducted to study the effect of T-cell immunity on the development of this pathology. Today, there is a steady upward trend in the prevalence of mpmns, which, on the one hand, is due to more effective methods of early diagnosis, an increase in patient overall survival, and early antitumor therapy (chemotherapy, radiation therapy), on the other hand, this trend may be associated with pathology of T-regulatory cellular immunity. T-regulatory cells play a strategic role in the development of immune homeostasis, and their function is closely related to the occurrence of a wide range of pathologies, including autoimmune diseases and malignant neoplasms. The article presents a clinical case of a patient with a confirmed diagnosis: mpmn, immune thrombocytopenia (idiopathic thrombocytopenic purpura). On prednisolone therapy, remission was achieved for 2 metachronous tumors and a complete hematological response for immune thrombocytopenia was obtained. there were no signs of hemorrhagic syndrome and complications during prednisone therapy. It is planned to continue monitoring the patient for metachronous tumors by a hematologist, an oncologist at the place of residence, as well as at the center for orphan diseases of the Moscow Regional Research Clinical Institute named after M. F. Vladimirsky with control of platelets and general condition.","PeriodicalId":37536,"journal":{"name":"Oncogematologiya","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immune thrombocytopenia in the aspect of multiple primary neoplasms\",\"authors\":\"R. V. Vardanyan, S. G. Zakharov, T. A. Mitina, P. A. Zeynalova, Yu. Yu. Chuksina, A. V. Zakharova\",\"doi\":\"10.17650/1818-8346-2023-18-3-44-49\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Multiple primary malignant neoplasms (MPMNs) is a complex process in which the development of 2 or more neoplasms simultaneously or after a certain interval is observed. MPMNs develop independently from each other within one or more organs. Many etiopathogenetic factors can cause MPMNs. Numerous studies have been conducted to study the effect of T-cell immunity on the development of this pathology. Today, there is a steady upward trend in the prevalence of mpmns, which, on the one hand, is due to more effective methods of early diagnosis, an increase in patient overall survival, and early antitumor therapy (chemotherapy, radiation therapy), on the other hand, this trend may be associated with pathology of T-regulatory cellular immunity. T-regulatory cells play a strategic role in the development of immune homeostasis, and their function is closely related to the occurrence of a wide range of pathologies, including autoimmune diseases and malignant neoplasms. The article presents a clinical case of a patient with a confirmed diagnosis: mpmn, immune thrombocytopenia (idiopathic thrombocytopenic purpura). On prednisolone therapy, remission was achieved for 2 metachronous tumors and a complete hematological response for immune thrombocytopenia was obtained. there were no signs of hemorrhagic syndrome and complications during prednisone therapy. It is planned to continue monitoring the patient for metachronous tumors by a hematologist, an oncologist at the place of residence, as well as at the center for orphan diseases of the Moscow Regional Research Clinical Institute named after M. F. Vladimirsky with control of platelets and general condition.\",\"PeriodicalId\":37536,\"journal\":{\"name\":\"Oncogematologiya\",\"volume\":\"19 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncogematologiya\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17650/1818-8346-2023-18-3-44-49\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncogematologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1818-8346-2023-18-3-44-49","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

多发原发恶性肿瘤(Multiple primary malignant neoms, MPMNs)是2个或2个以上肿瘤同时发生或在一定时间间隔后发生的复杂过程。MPMNs在一个或多个器官内相互独立地发育。许多致病因素可引起MPMNs。已经进行了大量的研究来研究t细胞免疫对这种病理发展的影响。今天,mpmns的患病率呈稳步上升的趋势,这一方面是由于更有效的早期诊断方法,患者总生存率的增加,以及早期抗肿瘤治疗(化疗,放疗),另一方面,这一趋势可能与t调节细胞免疫的病理有关。t调节细胞在免疫稳态的发展中起着战略性的作用,其功能与包括自身免疫性疾病和恶性肿瘤在内的多种病理的发生密切相关。本文提出了一个临床病例的病人确诊:mpmn,免疫性血小板减少症(特发性血小板减少性紫癜)。在强的松龙治疗下,2例异时性肿瘤获得缓解,免疫血小板减少症获得完全的血液学反应。在强的松治疗期间没有出血综合征和并发症的迹象。计划继续由一名血液学家、一名肿瘤学家在其居住地以及莫斯科地区临床研究所孤儿病中心对患者进行异时性肿瘤监测,控制血小板和一般情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Immune thrombocytopenia in the aspect of multiple primary neoplasms
Multiple primary malignant neoplasms (MPMNs) is a complex process in which the development of 2 or more neoplasms simultaneously or after a certain interval is observed. MPMNs develop independently from each other within one or more organs. Many etiopathogenetic factors can cause MPMNs. Numerous studies have been conducted to study the effect of T-cell immunity on the development of this pathology. Today, there is a steady upward trend in the prevalence of mpmns, which, on the one hand, is due to more effective methods of early diagnosis, an increase in patient overall survival, and early antitumor therapy (chemotherapy, radiation therapy), on the other hand, this trend may be associated with pathology of T-regulatory cellular immunity. T-regulatory cells play a strategic role in the development of immune homeostasis, and their function is closely related to the occurrence of a wide range of pathologies, including autoimmune diseases and malignant neoplasms. The article presents a clinical case of a patient with a confirmed diagnosis: mpmn, immune thrombocytopenia (idiopathic thrombocytopenic purpura). On prednisolone therapy, remission was achieved for 2 metachronous tumors and a complete hematological response for immune thrombocytopenia was obtained. there were no signs of hemorrhagic syndrome and complications during prednisone therapy. It is planned to continue monitoring the patient for metachronous tumors by a hematologist, an oncologist at the place of residence, as well as at the center for orphan diseases of the Moscow Regional Research Clinical Institute named after M. F. Vladimirsky with control of platelets and general condition.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncogematologiya
Oncogematologiya Medicine-Hematology
CiteScore
0.50
自引率
0.00%
发文量
67
审稿时长
10 weeks
期刊介绍: The main purpose of the Oncohematology journal is to publish up-to-date information on clinical, experimental and fundamental scientific research, diagnostics and treatment options, as well as other materials on all relevant issues in oncohematology. The journal’s objectives are to inform various specialists who provide advisory and therapeutic assistance to patients with oncohematological diseases about current advances, including the latest methods for the diagnosis and treatment of malignant blood diseases. The journal is an interdisciplinary scientific publication uniting doctors of various specialties ‒ hematologists, oncologists, surgeons, radiation therapists, intensive care specialist, pathologists, etc. ‒ to form an interdisciplinary therapy approach in order to improve the treatment efficacy of patients with hematological malignancies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信